title: Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
abstract: BACKGROUND
  We explored the feasibility and the histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma.
  
  
  METHODS
  Treatment consisted of concurrent radiotherapy (50 Gy within 5 weeks) and chemotherapy with 5-fluorouracil (300 mg/m(2)/day, 5 days/week, weeks 1-5) and cisplatin (20 mg/m(2)/day, days 1-5 and 29-33), followed by surgical resection of the pancreatic tumor in patients without progression.
  
  
  RESULTS
  In all, 41 patients were enrolled; 38 (93%) received >or=47 Gy; 30 patients (73%) received >or=75% of the prescribed doses of chemotherapy. Among 40 assessable patients, 27 (67.5%; 95% confidence interval 50.9% to 81.4%) were successfully treated (entire dose of radiation, >or=75% of the chemotherapy dose, no grade 4 non-hematologic toxicity). In all, 26 patients (63%) underwent surgical resection with curative intent and 21 (80.7%) had R0 resection. A total of 13 of 26 specimens (50%) presented a major pathologic response (>or=80% of severely degenerative cancer cells), with one complete pathologic response. Operative mortality was 2.8%. The local recurrence and 2-year survival rates were 4% and 32%, respectively, for the 26 operated patients.
  
  
  CONCLUSIONS
  This proposed preoperative scheme is feasible, does not prevent successful surgery, and provides antitumoral effect associated with major histopathological response in 50% of patients and a high R0 resection rate.
authors.affiliation: Department of Radiation Oncology, Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
authors.forename: R
authors.initials: R
authors.lastname: Le Scodan
authors.forename: F
authors.initials: F
authors.lastname: Mornex
authors.forename: N
authors.initials: N
authors.lastname: Girard
authors.forename: C
authors.initials: C
authors.lastname: Mercier
authors.forename: P-J
authors.initials: PJ
authors.lastname: Valette
authors.forename: M
authors.initials: M
authors.lastname: Ychou
authors.forename: F
authors.initials: F
authors.lastname: Bibeau
authors.forename: P
authors.initials: P
authors.lastname: Roy
authors.forename: J-Y
authors.initials: JY
authors.lastname: Scoazec
authors.forename: C
authors.initials: C
authors.lastname: Partensky
mesh_terms: D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D015996:Survival Rate
chemical_list: D002945:Cisplatin; D005472:Fluorouracil